- Home
- SNES vs BJDX Comparison
SNES vs BJDX Comparison
Compare SNES & BJDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNES
- BJDX
- Stock Information
- Founded
- SNES 2004
- BJDX 2015
- Country
- SNES United States
- BJDX United States
- Employees
- SNES N/A
- BJDX N/A
- Industry
- SNES Agricultural Chemicals
- BJDX Medical Specialities
- Sector
- SNES Industrials
- BJDX Health Care
- Exchange
- SNES Nasdaq
- BJDX Nasdaq
- Market Cap
- SNES 2.3M
- BJDX 2.2M
- IPO Year
- SNES 2016
- BJDX 2021
- Fundamental
- Price
- SNES $1.79
- BJDX $3.70
- Analyst Decision
- SNES Strong Buy
- BJDX
- Analyst Count
- SNES 1
- BJDX 0
- Target Price
- SNES $10.00
- BJDX N/A
- AVG Volume (30 Days)
- SNES 231.1K
- BJDX 38.2K
- Earning Date
- SNES 03-12-2025
- BJDX 05-14-2025
- Dividend Yield
- SNES N/A
- BJDX N/A
- EPS Growth
- SNES N/A
- BJDX N/A
- EPS
- SNES N/A
- BJDX N/A
- Revenue
- SNES $1,857,000.00
- BJDX N/A
- Revenue This Year
- SNES $130.53
- BJDX N/A
- Revenue Next Year
- SNES $80.00
- BJDX N/A
- P/E Ratio
- SNES N/A
- BJDX N/A
- Revenue Growth
- SNES 55.66
- BJDX N/A
- 52 Week Low
- SNES $1.75
- BJDX $3.03
- 52 Week High
- SNES $9.80
- BJDX $323.60
- Technical
- Relative Strength Index (RSI)
- SNES 31.20
- BJDX 46.70
- Support Level
- SNES $2.10
- BJDX $3.61
- Resistance Level
- SNES $2.34
- BJDX $4.02
- Average True Range (ATR)
- SNES 0.19
- BJDX 0.33
- MACD
- SNES -0.03
- BJDX -0.05
- Stochastic Oscillator
- SNES 9.09
- BJDX 20.31
About SNES SenesTech Inc.
SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company provides its solutions to the animal market, commercial markets, and food markets. It currently has two product lines of fertility control products: ContraPest and Evolve.
About BJDX Bluejay Diagnostics Inc.
Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.